Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FIRMAGON vs 8-HOUR BAYER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Gonadotropin-releasing hormone (Gn RH) receptor antagonist; competitively binds to Gn RH receptors in the anterior pituitary, rapidly reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby suppressing testosterone production in males.
Irreversibly acetylates cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), inhibiting prostaglandin and thromboxane A2 synthesis, leading to analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
FDA-approved for advanced prostate cancer (hormone-sensitive, metastatic or locally advanced),Off-label: Treatment of uterine fibroids, endometriosis, and precocious puberty
Relief of pain, fever, and inflammation,Reduction of risk of myocardial infarction in patients with previous MI or unstable angina,Prevention of recurrent ischemic stroke or transient ischemic attack
For advanced prostate cancer: 120 mg subcutaneously as a loading dose (two 60 mg injections), then 80 mg subcutaneously once monthly (one 80 mg injection) starting 28 days after the loading dose.
325-650 mg every 8 hours for pain/fever; 81-325 mg daily for cardiovascular prophylaxis.
Terminal elimination half-life is approximately 63 days after subcutaneous administration in patients with prostate cancer, allowing for monthly dosing schedules.
15-20 hours (terminal elimination half-life) for salicylate at therapeutic concentrations; prolonged to 20-30 hours at high doses due to saturation of hepatic metabolism (zero-order kinetics).
Degraded into peptides and amino acids; not a substrate for CYP450 enzymes.
Hepatic hydrolysis by esterases to salicylic acid, which is primarily conjugated in the liver via glucuronidation and glycine conjugation (salicyluric acid), with minor oxidation by cytochrome P450 (CYP2C9) to gentisic acid.
Primarily hepatobiliary; about 90% of the dose is eliminated in feces as unchanged drug, with less than 5% excreted renally as unchanged drug and metabolites.
Renal excretion of conjugated salicylate metabolites (75% as salicyluric acid, 10% as salicyl phenolic glucuronide, 5% as salicyl acyl glucuronide, 5% as gentisic acid); 10% free salicylate; approximately 10% eliminated in feces via bile.
Approximately 90% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
80-90% bound to albumin; binding is concentration-dependent and saturable.
Volume of distribution is approximately 10 L, indicating limited extravascular distribution consistent with a large peptide.
0.15-0.2 L/kg for salicylate; distributes into synovial fluid, CNS, and placental tissues; Vd increases in acidosis.
Subcutaneous administration: Bioavailability is approximately 50% relative to intravenous administration, with absorption characterized by a slow and sustained release profile.
Oral: Approximately 100% for immediate-release, but extended-release may have slightly reduced absorption (relative bioavailability 85-90% compared to immediate-release).
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (Cr Cl <30 m L/min). Use with caution.
Avoid in severe renal impairment (Cr Cl <30 m L/min). Use with caution and monitor for bleeding in moderate impairment. Reduce dose or extend interval.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
Avoid in severe hepatic impairment. Use with caution in moderate impairment; monitor liver function.
Safety and efficacy in pediatric patients have not been established. Not indicated for use in children.
Not recommended in children <12 years for viral infections due to Reye's syndrome risk (contraindicated).
No specific dose adjustment is recommended for elderly patients. Monitor for cardiovascular events and changes in bone density due to androgen deprivation.
Increased risk of GI bleeding and renal impairment; use lowest effective dose, monitor renal function and signs of bleeding.
Increased risk of QT interval prolongation; use caution in patients with congenital long QT syndrome, electrolyte abnormalities, or concomitant use of QT-prolonging drugs. Also, hypersensitivity reactions including anaphylaxis have been reported.
None
QT prolongation and ventricular arrhythmias (especially with hypokalemia or bradycardia),Hypersensitivity reactions (urticaria, angioedema, anaphylaxis),Tumor flare reaction (transient worsening of symptoms due to initial testosterone surge) - less common with degarelix compared to Gn RH agonists,Loss of bone mineral density with long-term use,Injection site reactions (pain, erythema, nodule, necrosis),Increased hepatic enzymes (transient and usually asymptomatic),Hyperglycemia and increased risk of diabetes (monitor blood glucose),Cardiovascular risks (myocardial infarction, stroke) in patients with pre-existing conditions
Increased risk of gastrointestinal bleeding and ulceration; Reye syndrome in children with viral illness; Hemorrhagic stroke risk with high doses; Impaired renal function in predisposed patients; Bronchospasm in aspirin-sensitive asthma; Anaphylactic reactions; Use caution in patients with hepatic impairment or G6PD deficiency.
Hypersensitivity to degarelix or any component of the formulation,Women of reproductive potential (pregnancy category X; can cause fetal harm),Severe renal impairment (Cr Cl < 30 m L/min) - insufficient data,Severe hepatic impairment (Child-Pugh class C) - not studied
Known hypersensitivity to NSAIDs or aspirin; Active peptic ulcer disease or GI bleeding; Severe renal impairment (e GFR <30 m L/min); Hemorrhagic diathesis; Children with viral infection (Reye syndrome); Third trimester of pregnancy; Severe hepatic impairment.
No significant food interactions. Avoid grapefruit juice if also taking certain antiarrhythmics or other QT-prolonging drugs. Maintain adequate calcium and vitamin D intake if at risk for bone loss.
Avoid alcohol; may increase risk of gastrointestinal bleeding. No specific food restrictions, but taking with food can reduce gastric irritation. Avoid high-dose vitamin C supplements as they may increase salicylate levels.
FIRMAGON (degarelix) is contraindicated in pregnancy. Gn RH antagonists like degarelix can cause fetal harm when administered to a pregnant woman. Based on findings from animal studies and its mechanism of action, degarelix is expected to increase the risk of first trimester pregnancy loss. Adequate human data are not available, but the drug should be avoided during pregnancy. If exposure occurs, inform the patient of the potential hazard.
First trimester: No well-controlled studies. Avoid use unless clearly needed. Second and third trimesters: Aspirin should be avoided due to risk of premature closure of ductus arteriosus, oligohydramnios, and increased risk of maternal and fetal bleeding. High doses may cause constriction of ductus arteriosus in utero and persistent pulmonary hypertension in newborn.
It is not known whether degarelix is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from degarelix, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Small amounts of aspirin are excreted in breast milk. M/P ratio not established. Use with caution in breastfeeding women; avoid high doses due to risk of Reye's syndrome in infants and potential for adverse effects on platelet function.
No dosage adjustment studies have been conducted in pregnant women. Degarelix is contraindicated in pregnancy, and use should be avoided. If inadvertent exposure occurs, no specific dose adjustment is recommended; instead, the drug should be discontinued and the patient counseled about fetal risks.
Pregnancy increases clearance of aspirin; however, dose adjustments are not routinely recommended due to narrow therapeutic index. Use lowest effective dose for shortest duration. Avoid in third trimester.
FIRMAGON (degarelix) is a Gn RH antagonist indicated for advanced prostate cancer. It does not cause testosterone flare like Gn RH agonists. Monitor serum calcium in patients with bone metastases due to risk of hypercalcemia. Injection site reactions are common; rotate sites and apply warm compresses. Use with caution in patients with congenital long QT syndrome or those on Class IA/III antiarrhythmics.
8-Hour Bayer is enteric-coated aspirin designed for extended release, reducing gastrointestinal irritation. Onset of action is delayed; not suitable for acute pain or rapid antiplatelet effect. Use with caution in patients with history of peptic ulcer disease or on anticoagulants. Monitor renal function in elderly or dehydrated patients. Avoid in children with viral illness due to Reye's syndrome risk.
This medication is given as an injection under the skin, usually every month.,It may cause injection site reactions like redness, swelling, or pain; applying a warm compress can help.,You may experience hot flashes, decreased libido, or erectile dysfunction.,Report any signs of allergic reaction (rash, itching, difficulty breathing) or unusual bleeding/bruising.,Regular blood tests are needed to monitor response and side effects.
Take with a full glass of water; do not crush or chew the tablet.,Do not use within 7 days before surgery due to bleeding risk.,If used for pain, consult a doctor if symptoms persist for more than 10 days.,Avoid alcohol while taking this medication to reduce stomach bleeding risk.,Seek medical attention for signs of bleeding (black stools, blood in vomit).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FIRMAGON vs 8-HOUR BAYER, answered by our medical review team.
FIRMAGON is a GnRH Antagonist that works by Gonadotropin-releasing hormone (Gn RH) receptor antagonist; competitively binds to Gn RH receptors in the anterior pituitary, rapidly reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby suppressing testosterone production in males.. 8-HOUR BAYER is a NSAID that works by Irreversibly acetylates cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), inhibiting prostaglandin and thromboxane A2 synthesis, leading to analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FIRMAGON and 8-HOUR BAYER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FIRMAGON is: For advanced prostate cancer: 120 mg subcutaneously as a loading dose (two 60 mg injections), then 80 mg subcutaneously once monthly (one 80 mg injection) starting 28 days after the loading dose.. The standard adult dose of 8-HOUR BAYER is: 325-650 mg every 8 hours for pain/fever; 81-325 mg daily for cardiovascular prophylaxis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FIRMAGON and 8-HOUR BAYER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FIRMAGON is classified as Category C. FIRMAGON (degarelix) is contraindicated in pregnancy. GnRH antagonists like degarelix can cause fetal harm when administered to a pregnant woman. Based on findings from animal stud. 8-HOUR BAYER is classified as Category C. First trimester: No well-controlled studies. Avoid use unless clearly needed. Second and third trimesters: Aspirin should be avoided due to risk of premature closure of ductus arte. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.